← Back to Search

Cholinergic Agonist

BRIMOCHOL™ PF for Presbyopia

Phase 3

Waitlist Available

Research Sponsored by Visus Therapeutics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline visit 1

Awards & highlights

Study Summary

This trial is testing two drugs, BRIMOCHOL™ PF and Carbachol PF, to see if they are safe and effective in treating presbyopia in people who are either emmetropic (have normal vision) or pseudophakic (have had cataract surgery).

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline visit 1

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline visit 1

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline visit 1 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change from baseline in near VA

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: BRIMOCHOL™ PFExperimental Treatment1 Intervention

A single drop in each eye at a visit.

Group II: Carbachol PFActive Control1 Intervention

A single drop in each eye at a visit.

Group III: Brimonidine tartrateActive Control1 Intervention

A single drop in each eye at a visit.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

BRIMOCHOL™ PF

2022

Completed Phase 3

~190

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Visus TherapeuticsLead Sponsor

2 Previous Clinical Trials

531 Total Patients Enrolled

2 Trials studying Presbyopia

531 Patients Enrolled for Presbyopia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are researchers still looking for participants for this trial?

"This study is looking for patients who fit the criteria and who are willing to participate. The trial was first posted on 3/30/2022 and was last edited on 9/30/2022."

Answered by AI

Is this experiment accessible in many locations within the city?

"There are a total of 10 sites where this trial is taking place. The locations are chosen so that potential patients would not have to travel far. They are situated in San Antonio, Rancho Cordova, Ogden and other locations."

Answered by AI

Does this research require a specific type of participant?

"170 individuals, both male and female, between the ages of 45 and 80 who have presbyopia, are being accepted into this study. Additionally, it is imperative that these patients are in good general health."

Answered by AI

Are people of all ages eligible for this research project?

"This study includes a broad age range of patients, with the oldest patient being 80 years old and the youngest being 45."

Answered by AI

How many people are eligible for this clinical trial?

"170 individuals that meet the pre-defined inclusion criteria are required for this clinical trial. The study is taking place at various locations, such as the Visus Therapeutics Investigative Center in San Antonio, Texas and Total Eye Care, PA in Rancho Cordova, California."

Answered by AI

Could you explain the potential health risks associated with BRIMOCHOL™ PF?

"BRIMOCHOL™ PF is a Phase 3 clinical trial medication, meaning that there is some evidence of its efficacy and that it has undergone multiple rounds of testing for safety. Our team at Power estimates its safety to be a 3 on a scale of 1 to 3."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia

2022. "Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05270863.